Plain-English translation of NCT07651878 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new cell therapy called in people with chronic myeloid leukemia (a blood cancer) who are on long-term treatment but still have signs of cancer cells in their blood. The goal is to see if adding this immune cell treatment to your current medication can help your immune system fight the remaining cancer cells more effectively, potentially allowing you to reduce or eventually stop your current medications.
Many people with this type of blood cancer stay on medications for years or decades, even when the cancer is well-controlled. This treatment is being developed to strengthen the body's own immune defenses so the cancer can be kept in check with lower doses of medication—or possibly none at all—giving patients more treatment freedom.
You likely qualify if…
You likely don't qualify if…
You will receive six injections of the medication over the first 6 weeks (four injections given every 2 weeks, then two more at weeks 14 and 18), given as small shots under the skin. The active treatment phase lasts about 5 months, after which you will have regular check-ups and blood tests for a total of 3 years from the start of the trial. You will continue taking your regular blood cancer medication throughout the study while researchers monitor whether the new treatment helps you eventually reduce or stop that medication.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
Norway